Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-baseline Relative to Baseline
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline (Day 1) and up to approximately 263 weeks
What was measured
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Kappa Light (K Lt), Lambda (λ),Monoclonal (Mc), Protein (P), Change (Cge), Alpha (α), Beta (β), Creatine Kinase (CK), Gamma (γ) ,Immunoglobulin (I-Globulin), Indirect (In.)\]
Analysis population: Safety Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories. Participants were counted more than once within some categories, hence the percentages may not add up to 100%.
Groups in this outcome
Belantamab Mafodotin
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
Pomalidomide Plus Dexamethasone
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
217
Pomalidomide Plus Dexamethasone
102
Reported measurements
Calcium, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
215
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
42
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
40
Not reported
Not reported
Not reported
Not reported
Calcium, Change to Normal (N) or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
215
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
138
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
49
Not reported
Not reported
Not reported
Not reported
Calcium, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
215
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
39
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
10
Not reported
Not reported
Not reported
Not reported
Carbon Dioxide, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
176
Pomalidomide Plus Dexamethasone
80
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
61
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
28
Not reported
Not reported
Not reported
Not reported
Carbon Dioxide, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
176
Pomalidomide Plus Dexamethasone
80
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
93
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
44
Not reported
Not reported
Not reported
Not reported
Carbon Dioxide, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
176
Pomalidomide Plus Dexamethasone
80
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
31
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
Chloride, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
211
Pomalidomide Plus Dexamethasone
96
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
30
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
Chloride, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
211
Pomalidomide Plus Dexamethasone
96
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
132
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
56
Not reported
Not reported
Not reported
Not reported
Chloride, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
211
Pomalidomide Plus Dexamethasone
96
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
54
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
31
Not reported
Not reported
Not reported
Not reported
Protein, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
214
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
63
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
42
Not reported
Not reported
Not reported
Not reported
Protein, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
214
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
135
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
51
Not reported
Not reported
Not reported
Not reported
Protein, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
214
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
19
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
K Lt C (Chain), Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
206
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
30
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
K Lt C, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
206
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
169
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
78
Not reported
Not reported
Not reported
Not reported
K Lt C, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
206
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
K Lt C,Free, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
K Lt C, Free, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
K Lt C, Free, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
K Lt C,Free/λ Lt C, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
27
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
K Lt C,Free/λ Lt C, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
27
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
K Lt C,Free/λ Lt C, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
27
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
13
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
λ Lt C, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
209
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
46
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
λ Lt C, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
209
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
159
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
83
Not reported
Not reported
Not reported
Not reported
λ Lt C, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
209
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
λ Lt C, Free, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
λ Lt C, Free, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
λ Lt C, Free, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
11
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Mc Protein, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
Mc Protein, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
9
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Mc Protein Spike, Change to N or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
200
Pomalidomide Plus Dexamethasone
89
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
193
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
88
Not reported
Not reported
Not reported
Not reported
Mc Protein Spike, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
200
Pomalidomide Plus Dexamethasone
89
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Mc P Spike/Total P, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
200
Pomalidomide Plus Dexamethasone
89
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
193
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
88
Not reported
Not reported
Not reported
Not reported
Mc P Spike/Total P, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
200
Pomalidomide Plus Dexamethasone
89
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
No. of Mc P Spikes, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
200
Pomalidomide Plus Dexamethasone
89
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
193
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
88
Not reported
Not reported
Not reported
Not reported
No. of Mc P Spikes, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
200
Pomalidomide Plus Dexamethasone
89
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
α -1 Globulin/Total P, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
α -1 Globulin/Total P,Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
103
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
41
Not reported
Not reported
Not reported
Not reported
α -1 Globulin/Total P, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
104
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
57
Not reported
Not reported
Not reported
Not reported
α -2 Globulin/Total P, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
α -2 Globulin/Total P, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
127
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
47
Not reported
Not reported
Not reported
Not reported
α -2 Globulin/Total P, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
72
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
49
Not reported
Not reported
Not reported
Not reported
β -2 microglobulin, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
42
Pomalidomide Plus Dexamethasone
19
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
41
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
18
Not reported
Not reported
Not reported
Not reported
β -2 microglobulin, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
42
Pomalidomide Plus Dexamethasone
19
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
CK , Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
0
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Direct Bilirubin, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
191
Pomalidomide Plus Dexamethasone
91
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Direct Bilirubin, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
191
Pomalidomide Plus Dexamethasone
91
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
143
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
60
Not reported
Not reported
Not reported
Not reported
Direct Bilirubin, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
191
Pomalidomide Plus Dexamethasone
91
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
46
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
30
Not reported
Not reported
Not reported
Not reported
γ Globulin/Total P, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
50
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
γ Globulin/Total P, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
157
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
77
Not reported
Not reported
Not reported
Not reported
γ Globulin/Total P, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
98
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
I-Globulin A, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
15
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
I-Globulin A, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
15
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
13
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
I-Globulin A,, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
15
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
I-Globulin G, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
I-Globulin G, Change to Normal or No Change
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
I-Globulin G, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
I-Globulin M, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
16
Pomalidomide Plus Dexamethasone
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
I-Globulin M, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
16
Pomalidomide Plus Dexamethasone
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
In. Bilirubin, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
In. Bilirubin, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
In. Bilirubin, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Phosphate, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
56
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
42
Not reported
Not reported
Not reported
Not reported
Phosphate, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
123
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
43
Not reported
Not reported
Not reported
Not reported
Phosphate, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
210
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
39
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
Thyrotropin, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
65
Pomalidomide Plus Dexamethasone
22
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Thyrotropin, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
65
Pomalidomide Plus Dexamethasone
22
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
42
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
Thyrotropin, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
65
Pomalidomide Plus Dexamethasone
22
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Thyroxine, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
64
Pomalidomide Plus Dexamethasone
21
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
Thyroxine, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
64
Pomalidomide Plus Dexamethasone
21
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
42
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
Thyroxine, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
64
Pomalidomide Plus Dexamethasone
21
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
13
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Troponin I, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Urate, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
211
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
46
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14
Not reported
Not reported
Not reported
Not reported
Urate, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
211
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
128
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
67
Not reported
Not reported
Not reported
Not reported
Urate, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
211
Pomalidomide Plus Dexamethasone
97
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
44
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
Urea Nitrogen, Decrease to Low
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
83
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Urea Nitrogen, Cge to N or No Cge
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
83
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
40
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
19
Not reported
Not reported
Not reported
Not reported
Urea Nitrogen, Increase to High
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
83
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
37
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
42
group Id
OG001
value
40
denoms
counts
group Id
OG000
value
215
group Id
OG001
value
97
units
Participants
title
Calcium, Decrease to Low
categories
measurements
group Id
OG000
value
138
group Id
OG001
value
49
denoms
counts
group Id
OG000
value
215
group Id
OG001
value
97
units
Participants
title
Calcium, Change to Normal (N) or No Change
categories
measurements
group Id
OG000
value
39
group Id
OG001
value
10
denoms
counts
group Id
OG000
value
215
group Id
OG001
value
97
units
Participants
title
Calcium, Increase to High
categories
measurements
group Id
OG000
value
61
group Id
OG001
value
28
denoms
counts
group Id
OG000
value
176
group Id
OG001
value
80
units
Participants
title
Carbon Dioxide, Decrease to Low
categories
measurements
group Id
OG000
value
93
group Id
OG001
value
44
denoms
counts
group Id
OG000
value
176
group Id
OG001
value
80
units
Participants
title
Carbon Dioxide, Change to N or No Change
categories
measurements
group Id
OG000
value
31
group Id
OG001
value
12
denoms
counts
group Id
OG000
value
176
group Id
OG001
value
80
units
Participants
title
Carbon Dioxide, Increase to High
categories
measurements
group Id
OG000
value
30
group Id
OG001
value
12
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
96
units
Participants
title
Chloride, Decrease to Low
categories
measurements
group Id
OG000
value
132
group Id
OG001
value
56
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
96
units
Participants
title
Chloride, Change to N or No Change
categories
measurements
group Id
OG000
value
54
group Id
OG001
value
31
denoms
counts
group Id
OG000
value
211
group Id
OG001
value
96
units
Participants
title
Chloride, Increase to High
categories
measurements
group Id
OG000
value
63
group Id
OG001
value
42
denoms
counts
group Id
OG000
value
214
group Id
OG001
value
97
units
Participants
title
Protein, Decrease to Low
categories
measurements
group Id
OG000
value
135
group Id
OG001
value
51
denoms
counts
group Id
OG000
value
214
group Id
OG001
value
97
units
Participants
title
Protein, Change to N or No Change
categories
measurements
group Id
OG000
value
19
group Id
OG001
value
6
denoms
counts
group Id
OG000
value
214
group Id
OG001
value
97
units
Participants
title
Protein, Increase to High
denoms
counts
group Id
OG000
value
217
group Id
OG001
value
102
units
Participants
description
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Kappa Light (K Lt), Lambda (λ),Monoclonal (Mc), Protein (P), Change (Cge), Alpha (α), Beta (β), Creatine Kinase (CK), Gamma (γ) ,Immunoglobulin (I-Globulin), Indirect (In.)\]
groups
description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin
description
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
id
OG001
title
Pomalidomide Plus Dexamethasone
param Type
COUNT_OF_PARTICIPANTS
population Description
Safety Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories. Participants were counted more than once within some categories, hence the percentages may not add up to 100%.
reporting Status
POSTED
time Frame
Baseline (Day 1) and up to approximately 263 weeks
title
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-baseline Relative to Baseline
Triangle